Intellectual property and COVID-19 medicines: why a WTO waiver may not be enough
By Enrico Bonadio, Reader in Intellectual Property Law, City, University of London
Dhanay M. Cadillo Chandler, Postdoctoral research fellow, University of Turku
The COVID-19 pandemic, and the race to make vaccines and other useful technologies more accessible to people around the world, has once again highlighted the tension between intellectual property rights and the promotion of public health.
There is no doubt that the monopolies offered by exclusive rights such as patents are necessary to incentivise pharmaceutical companies to invest huge resources and develop useful drugs. These rights help manufacturers…
Read complete article
© The Conversation
- Wednesday, February 24, 2021